Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1556 related articles for article (PubMed ID: 26314218)

  • 21. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
    Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
    Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB
    Cell Cycle; 2015; 14(22):3602-12. PubMed ID: 26506264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.
    Bodo J; Sedlak J; Maciejewski JP; Almasan A; Hsi ED
    Apoptosis; 2011 Sep; 16(9):914-23. PubMed ID: 21667043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
    Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
    BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
    Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
    Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
    Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
    Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
    Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
    Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F
    Oncotarget; 2016 Sep; 7(36):58142-58147. PubMed ID: 27494885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
    Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.
    Eto S; Saeki K; Yoshitake R; Yoshimoto S; Shinada M; Ikeda N; Kamoto S; Tanaka Y; Kato D; Maeda S; Tsuboi M; Chambers J; Uchida K; Nishimura R; Nakagawa T
    PLoS One; 2019; 14(6):e0218382. PubMed ID: 31206526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
    Yang B; Yu D; Liu J; Yang K; Wu G; Liu H
    Tumour Biol; 2015 Jul; 36(7):5051-61. PubMed ID: 25649979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
    Brem EA; Thudium K; Khubchandani S; Tsai PC; Olejniczak SH; Bhat S; Riaz W; Gu J; Iqbal A; Campagna R; Knight J; Mavis C; Hoskin P; Deeb G; Gibbs JF; Fetterly G; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2011 Jun; 153(5):599-611. PubMed ID: 21492126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
    Chun SG; Zhou W; Yee NS
    Cancer Biol Ther; 2009 Jul; 8(14):1328-39. PubMed ID: 19421011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
    Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
    Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
    Jeon MJ; Yu ES; Choi CW; Kim DS
    Korean J Intern Med; 2023 Nov; 38(6):893-902. PubMed ID: 37599392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 78.